Do autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children?
IV autologous bone marrow-derived mononuclear cell therapy is associated with lower treatment intensity required to manage intracranial pressure, associated severity of organ injury, and duration of neurointensive care following severe traumatic brain injury. This may corroborate preclinical data that autologous bone marrow-derived mononuclear cell therapy attenuates the effects of inflammation in the early post-traumatic brain injury period.
This similarity suggests a possible causal relationship between the energy density deposition and the repair rate or the probability of dsb repair.